Insider · CIK 0002000226

Jewell Christopher M

Reports to the SEC for 1 company · FREDERICK, MD

sec.gov

Transactions

Companies

Filings

CIK

0002000226

Forms 4 and 5

Insider transactions

20 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-01-10	RNACCartesian Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+9,000 sh	$3.23	+$29.1K	62,490
2025-01-10	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−9,000 sh	—	—	67,432
2025-01-06	RNACCartesian Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,286 sh	$16.83	−$21.6K	53,490
2025-01-03	RNACCartesian Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,264 sh	$16.72	−$21.1K	54,776
2025-01-02	RNACCartesian Therapeutics, Inc.A Award	Chief Scientific Officer	AAward	+16.1K sh	—	—	56,040
2025-01-02	RNACCartesian Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+47.4K sh	—	—	47,400
2024-11-20	RNACCartesian Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+14K sh	$3.23	+$45.2K	39,940
2024-11-20	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−14K sh	—	—	76,432
2024-11-15	RNACCartesian Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+16.1K sh	$3.23	+$51.9K	42,005
2024-11-15	RNACCartesian Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−16.1K sh	$17.06	−$274K	25,940
2024-11-15	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−16.1K sh	—	—	90,432
2024-11-14	RNACCartesian Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+36.1K sh	$3.23	+$116K	61,990
2024-11-14	RNACCartesian Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−18.6K sh	$16.34	−$303K	43,440
2024-11-14	RNACCartesian Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−17.5K sh	$17.02	−$298K	25,940
2024-11-14	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−36.1K sh	—	—	106,497
2024-04-08	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−4,276.454 sh	—	—	0
2024-04-08	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+143K sh	—	—	142,547
2024-01-02	RNACCartesian Therapeutics, Inc.A Award	Chief Scientific Officer	AAward	+778K sh	—	—	778,200
2024-01-02	RNACCartesian Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+998K sh	—	—	998,000
2023-11-13	RNACCartesian Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Scientific Officer	AAward	+4,276.454 sh	—	—	4,276.454

Recent filings

Accepted (ET)
Jan 134
Jewell Christopher M0001453687-25-000045
SEC(opens sec.gov)
Jan 74
Jewell Christopher M0001453687-25-000038
SEC(opens sec.gov)
Jan 64
Jewell Christopher M0001453687-25-000027
SEC(opens sec.gov)
Nov 214
Jewell Christopher M0001453687-24-000138
SEC(opens sec.gov)
Nov 184
Jewell Christopher M0001453687-24-000128
SEC(opens sec.gov)
Apr 104
Jewell Christopher M0001453687-24-000061
SEC(opens sec.gov)
Jan 44
Jewell Christopher M0001453687-24-000026
SEC(opens sec.gov)
Nov 154
Jewell Christopher M0001062993-23-020923
SEC(opens sec.gov)

Companies

Cartesian Therapeutics, Inc.Chief Scientific OfficerRNAC

Address

C/O CARTESIAN THERAPEUTICS, INC. 7495 NEW HORIZON WAY

FREDERICK, MD, 21703